Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4068-4070

  Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

CANCER CHEMOTHERAPY; COPY NUMBER VARIATION; DRUG COST; ECONOMIC ASPECT; EDITORIAL; HEALTH CARE COST; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 80755181119     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.8349     Document Type: Editorial

References (11)

1. Coate LE, John T, Tsao MS, et al.: Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 10:1001-1010, 2009
2. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005 (Pubitemid 41058345)
3. Zhu CQ, da Cunha Santos G, Ding K, et al.: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:4268-4275, 2008
4. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al.: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042, 2006 (Pubitemid 46631407)
5. Douillard JY, Shepherd FA, Hirsh V, et al.: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 28:744-752, 2010
6. Fukuoka M, Wu Y-L, Thongprasert S, et al.: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866-2874, 2011
7. Rosell R, Moran T, Queralt C, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
8. Brugger W, Triller N, Blasinska-Morawiec M, et al.: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113-4120, 2011
9. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
10. Bradbury PA, Tu D, Seymour L, et al.: Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 102:298-306, 2010
11. Coate LE, Shepherd FA: Maintenance therapy in advanced non-small cell lung cancer. J Thorac Oncol 5:723-734, 2010